Depakote ANDA Didn't Violate Injunction: Court

Law360, New York (October 11, 2007, 12:00 AM EDT) -- Apotex Inc.'s third trip to the Federal Circuit in its long-running patent spat with Abbott Laboratories over the epilepsy drug Depakote on Thursday yielded a reversal of a lower court’s ruling that had found the generics maker in contempt of an earlier injunction.

That ruling of contempt had been handed down last year by the Chicago district court, which ruled that Apotex’s filing of a second Abbreviated New Drug Application for a different chemical version of Abbott’s Depakote-branded divalproex sodium constituted a violation of an injunction...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.